• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型7-氨基吡唑并[3,4-b]哒嗪骨架的高亲和力腺苷A1/A2A受体拮抗剂的发现。

Discovery of a High Affinity Adenosine A/A Receptor Antagonist with a Novel 7-Amino-pyrazolo[3,4-]pyridazine Scaffold.

作者信息

Suchankova Anna, Stampelou Margarita, Koutsouki Klontiana, Pousias Athanasios, Dhingra Lakshiv, Barkan Kerry, Pouli Nicole, Marakos Panagiotis, Tenta Roxane, Kolocouris Antonios, Lougiakis Nikolaos, Ladds Graham

机构信息

Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K.

Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece.

出版信息

ACS Med Chem Lett. 2022 May 31;13(6):923-934. doi: 10.1021/acsmedchemlett.2c00052. eCollection 2022 Jun 9.

DOI:10.1021/acsmedchemlett.2c00052
PMID:35707146
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9190043/
Abstract

Here we describe the design and synthesis of pyrazolo[3,4-]pyridazines as adenosine receptor (AR) ligands. We demonstrate that the introduction of a 3-phenyl group, together with a 7-benzylamino and 1-methyl group at the pyrazolopyridazine scaffold, generated the antagonist compound , which displayed 21 nM affinity and a residence time of ∼60 min, for the human AR, 55 nM affinity and a residence time of ∼73 min, for the human AR and 1.7 μΜ affinity for the human AR while not being toxic. Strikingly, the 2-methyl analog of , , had no significant affinity. Docking calculations and molecular dynamics simulations of the ligands inside the orthosteric binding area suggested that the 2-methyl group in hinders the formation of hydrogen bonding interactions with N which are considered critical for the stabilization inside the orthosteric binding cavity. We, therefore, demonstrate that is a novel scaffold for the development of high affinity AR ligands. From the mutagenesis experiments the biggest effect was observed for the Y271A mutation which caused an ∼10-fold reduction in the binding affinity of .

摘要

在此,我们描述了作为腺苷受体(AR)配体的吡唑并[3,4 - ]哒嗪的设计与合成。我们证明,在吡唑并哒嗪骨架上引入一个3 - 苯基,以及一个7 - 苄基氨基和一个1 - 甲基,生成了拮抗剂化合物,其对人AR显示出21 nM的亲和力和约60分钟的驻留时间,对人AR显示出55 nM的亲和力和约73分钟的驻留时间,对人AR的亲和力为1.7 μΜ,且无毒。引人注目的是,化合物的2 - 甲基类似物没有显著亲和力。在正构结合区域内对配体进行对接计算和分子动力学模拟表明,中的2 - 甲基基团阻碍了与N形成氢键相互作用,而这种相互作用被认为对在正构结合腔内的稳定至关重要。因此,我们证明是开发高亲和力AR配体的新型骨架。从诱变实验中观察到,Y271A突变的影响最大,导致的结合亲和力降低了约10倍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/199f1d2a6e18/ml2c00052_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/883bae0c490a/ml2c00052_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/f7d14ddf3b54/ml2c00052_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/58e337863cea/ml2c00052_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/001a89e39199/ml2c00052_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/79d4d193d23e/ml2c00052_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/199f1d2a6e18/ml2c00052_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/883bae0c490a/ml2c00052_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/f7d14ddf3b54/ml2c00052_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/58e337863cea/ml2c00052_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/001a89e39199/ml2c00052_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/79d4d193d23e/ml2c00052_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70a3/9190043/199f1d2a6e18/ml2c00052_0003.jpg

相似文献

1
Discovery of a High Affinity Adenosine A/A Receptor Antagonist with a Novel 7-Amino-pyrazolo[3,4-]pyridazine Scaffold.新型7-氨基吡唑并[3,4-b]哒嗪骨架的高亲和力腺苷A1/A2A受体拮抗剂的发现。
ACS Med Chem Lett. 2022 May 31;13(6):923-934. doi: 10.1021/acsmedchemlett.2c00052. eCollection 2022 Jun 9.
2
Dual A1/A3 Adenosine Receptor Antagonists: Binding Kinetics and Structure-Activity Relationship Studies Using Mutagenesis and Alchemical Binding Free Energy Calculations.双重 A1/A3 腺苷受体拮抗剂:使用诱变和化学结合自由能计算的结合动力学和构效关系研究。
J Med Chem. 2022 Oct 13;65(19):13305-13327. doi: 10.1021/acs.jmedchem.2c01123. Epub 2022 Sep 29.
3
Insights to the Binding of a Selective Adenosine A Receptor Antagonist Using Molecular Dynamic Simulations, MM-PBSA and MM-GBSA Free Energy Calculations, and Mutagenesis.利用分子动力学模拟、MM-PBSA 和 MM-GBSA 自由能计算以及突变分析探讨选择性腺苷 A 受体拮抗剂的结合机制。
J Chem Inf Model. 2019 Dec 23;59(12):5183-5197. doi: 10.1021/acs.jcim.9b00751. Epub 2019 Dec 3.
4
Development of Covalent, Clickable Probes for Adenosine A and A Receptors.用于腺苷 A 和 A 受体的共价、可点击探针的开发。
J Med Chem. 2021 Jun 24;64(12):8161-8178. doi: 10.1021/acs.jmedchem.0c02169. Epub 2021 Jun 14.
5
Structural Characterization of Agonist Binding to an A Adenosine Receptor through Biomolecular Simulations and Mutagenesis Experiments.通过生物分子模拟和突变实验研究激动剂与 A 腺苷受体的结合结构。
J Med Chem. 2019 Oct 10;62(19):8831-8846. doi: 10.1021/acs.jmedchem.9b01164. Epub 2019 Sep 27.
6
A facile and novel synthesis of N(2)-, C(6)-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists.一种简便新颖的 N(2)-、C(6)-取代的吡唑并[3,4-d]嘧啶-4 羧酸酯衍生物的合成方法,作为腺苷受体拮抗剂。
Eur J Med Chem. 2015 Mar 6;92:784-98. doi: 10.1016/j.ejmech.2015.01.046. Epub 2015 Jan 22.
7
Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model.作为强效A1腺苷拮抗剂的取代吡唑并[3,4 - b]吡啶:A1牛受体模型的合成、生物学评价及开发
ChemMedChem. 2008 Jun;3(6):898-913. doi: 10.1002/cmdc.200700355.
8
Development of novel adenosine receptor ligands based on the 3-amidocoumarin scaffold.基于 3-酰胺香豆素骨架的新型腺苷受体配体的开发。
Bioorg Chem. 2015 Aug;61:1-6. doi: 10.1016/j.bioorg.2015.05.008. Epub 2015 May 22.
9
Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.新型 A2A 和 A3 腺苷受体拮抗剂 C9 和 C2 取代的吡唑并[4,3-e]-1,2,4-三唑并[1,5-c]嘧啶的设计、合成及生物学评价
J Med Chem. 2003 Mar 27;46(7):1229-41. doi: 10.1021/jm021023m.
10
Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes.缺氧时腺苷A1和A3受体激活对离体大鼠心肌细胞的心脏保护作用。
Mol Cell Biochem. 2001 Jan;217(1-2):143-52. doi: 10.1023/a:1007209321969.

引用本文的文献

1
Synthetic Small-Molecule Ligands Targeted to Adenosine Receptors: Is There Potential Towards Ischemic Heart Disease?靶向腺苷受体的合成小分子配体:对缺血性心脏病有潜在作用吗?
Cells. 2025 Aug 7;14(15):1219. doi: 10.3390/cells14151219.
2
Discovery and Structure-Activity Relationship Studies of Novel Adenosine A Receptor-Selective Agonists.新型腺苷 A 受体选择性激动剂的发现和构效关系研究。
J Med Chem. 2022 Nov 10;65(21):14864-14890. doi: 10.1021/acs.jmedchem.2c01414. Epub 2022 Oct 21.

本文引用的文献

1
New bioactive 5-arylcarboximidamidopyrazolo[3,4-c]pyridines: Synthesis, cytotoxic activity, mechanistic investigation and structure-activity relationships.新型生物活性 5-芳基甲脒基吡唑并[3,4-c]吡啶:合成、细胞毒性活性、机制研究和构效关系。
Eur J Med Chem. 2021 Jun 5;218:113387. doi: 10.1016/j.ejmech.2021.113387. Epub 2021 Mar 19.
2
Pharmacological characterisation of novel adenosine A receptor antagonists.新型腺苷 A 受体拮抗剂的药理学特性。
Sci Rep. 2020 Nov 27;10(1):20781. doi: 10.1038/s41598-020-74521-y.
3
Insights to the Binding of a Selective Adenosine A Receptor Antagonist Using Molecular Dynamic Simulations, MM-PBSA and MM-GBSA Free Energy Calculations, and Mutagenesis.
利用分子动力学模拟、MM-PBSA 和 MM-GBSA 自由能计算以及突变分析探讨选择性腺苷 A 受体拮抗剂的结合机制。
J Chem Inf Model. 2019 Dec 23;59(12):5183-5197. doi: 10.1021/acs.jcim.9b00751. Epub 2019 Dec 3.
4
Structural Characterization of Agonist Binding to an A Adenosine Receptor through Biomolecular Simulations and Mutagenesis Experiments.通过生物分子模拟和突变实验研究激动剂与 A 腺苷受体的结合结构。
J Med Chem. 2019 Oct 10;62(19):8831-8846. doi: 10.1021/acs.jmedchem.9b01164. Epub 2019 Sep 27.
5
End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design.基于 MM/PBSA 和 MM/GBSA 的终点结合自由能计算:在药物设计中的策略与应用。
Chem Rev. 2019 Aug 28;119(16):9478-9508. doi: 10.1021/acs.chemrev.9b00055. Epub 2019 Jun 24.
6
Targeting the A adenosine receptor to treat cytokine release syndrome in cancer immunotherapy.靶向 A 型腺苷受体治疗癌症免疫疗法中的细胞因子释放综合征。
Drug Des Devel Ther. 2019 Jan 30;13:491-497. doi: 10.2147/DDDT.S195294. eCollection 2019.
7
Structure of the adenosine-bound human adenosine A receptor-G complex.人源腺苷受体-G 复合物结合腺苷的结构。
Nature. 2018 Jun;558(7711):559-563. doi: 10.1038/s41586-018-0236-6. Epub 2018 Jun 20.
8
Dose-dependent effects of adenosine antagonists on tacrine-induced tremulous jaw movements.腺苷拮抗剂对他克林诱发的震颤下颌运动的剂量依赖性影响。
Eur J Pharmacol. 2018 Aug 15;833:364-369. doi: 10.1016/j.ejphar.2018.06.004. Epub 2018 Jun 6.
9
Design, synthesis, DFT study and antifungal activity of the derivatives of pyrazolecarboxamide containing thiazole or oxazole ring.含噻唑或恶唑环的吡唑甲酰胺衍生物的设计、合成、密度泛函理论研究及抗真菌活性
Eur J Med Chem. 2018 Apr 10;149:170-181. doi: 10.1016/j.ejmech.2018.02.036. Epub 2018 Feb 21.
10
Structures of Human A and A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity.人 A 和 A 腺苷受体与黄嘌呤结构揭示了选择性的决定因素。
Structure. 2017 Aug 1;25(8):1275-1285.e4. doi: 10.1016/j.str.2017.06.012. Epub 2017 Jul 14.